Programme

TUESDAY, 6 FEBRUARY 2018

PRE-CONGRESS DAY FOR NURSES, PHYSIOTHERAPISTS, AND PSYCHOSOCIAL PROFESSIONALS
10:30 – 17:30 See Programme
YOUNG INVESTIGATORS WORKSHOP
13:00 – 17:00 See Programme

WEDNESDAY, 7 FEBRUARY 2018

MULTIDISCIPLINARY EDUCATIONAL SESSION Chairs: Jan Blatny and Víctor Jiménez Yuste Auditorio A / Plenary Hall
09:30 – 11:00 Radiosynovectomy – an important treatment option for patients with target joint  Jan Blatny, Víctor Jiménez Yuste, E. Carlos Rodriguez-Merchan, Sébastien Lobet, Sara Garcia Barcenilla, Daniel Aníbal García Diego
11:00 – 11:30 Coffee Break
INDUSTRY SPONSORED SESSIONS
11:30 – 13:00 Industry sponsored sessions
13:00 – 14:00 Lunch Break
14:00 – 15:30 Industry sponsored sessions
15:30 – 16:00 Coffee Break
16:00 – 17:30 Industry sponsored sessions
17:30 – 18:00 Coffee Break
18:00 – 19:30 Industry sponsored session
19:30 – 20:30 WELCOME RECEPTION Poster & Catering Area

THURSDAY, 8 FEBRUARY 2018

08:45 – 09:00 WELCOME AND INTRODUCTION Víctor Jiménez Yuste and Cédric Hermans Auditorio A / Plenary Hall
09:00 – 10:30 SESSION 1: Inhibitors from Basic Science to Clinical Management Chairs: Karin Fijn van Draat and Maria Teresa Alvarez-Roman Auditorio A / Plenary Hall
09:00 – 09:30 The role of innate immunology Eduardo López Collazo
09:30 – 10:00 Prophylaxis in inhibitor patients Pål Andre Holme
10:00 – 10:30 Is the type of product important in inhibitor development? Samantha Gouw
10:30 – 11:00 Coffee Break/Poster Viewing  Poster & Catering Area
11:00 – 12:30 SESSION 2: Platelets Chairs: Riitta Lassila and Jose Mateo Auditorio A / Plenary Hall
11:00 – 11:30 Old and novel platelet disorder: experience in the Spanish national project José Rivera
11:30 – 12:00 Treatment of inherited thrombocytopenia Carlo Balduini
12:00 – 12:30 Congenital and immune-mediated thrombotic thrombocytopenic purpura Johanna Kremer Hovinga
12:30 – 13:30   Lunch break/Poster Viewing /EAHAD Annual General Meeting  Poster & Catering Area
13:30 – 15:00 SESSION 3: Economics of Haemophilia Chairs: Philippe de Moerloose and Santiago Bonanad Auditorio A / Plenary Hall
13:30 – 14:00 Pharmacoeconomics of haemophilia care Lieve Annemans
14:00 – 14:30 EHC PARTNERS Programme Brian O’Mahony
14:30 – 15:00 Challenges and changes in the plasma products sector Bruno Santoni
15:00 – 15:30 Coffee Break/Poster Viewing  Poster & Catering Area
15:30 – 17:00 SESSION 4: More than Factor Administration Chairs: Martin Bedford and Ramiro Nuñez Auditorio A / Plenary Hall
15:30 – 16:00 Ultrasound imaging in acute bleeding and haemophilic arthropathy Carlo Martinoli
16:00 – 16:30 The management of acute musculoskeletal bleeding events Stephen Classey
16:30 – 17:00 Family-based educational programme on self-management : A structured approach Piet de Kleijn
17:00 – 17:15 Poster Viewing  Poster Area
17:15 – 18:45 SESSION 5: Outside the Joints Chairs: Hervé Chambost and Javier Batlle Auditorio A / Plenary Hall
17:15 – 17:45 Can we now forget about hepatitis C in haemophilia? Juan Berenguer
17:45 – 18:15 Intracranial Haemorrhage in inherited bleeding disorders Ri Liesner
18:15 – 18:45 Women’s issues in inherited bleeding disorders Sophie Susen
20:00 – 00:00 Congress Networking Evening

FRIDAY, 9 FEBRUARY 2018

07:45 – 08:30 MORNING CASE Chairs: Michael Makris and Cédric Hermans Auditorio A / Plenary Hall
New products and rules for switching Flora Peyvandi
08:30 – 10:00 SESSION 6: SLAM Chairs: Robert Klamroth and Marie Eva Mingot Auditorio A / Plenary Hall
OR01 IMPLEMENTATION OF THE FRENCH PRIMARY LONGTERM PROPHYLAXIS GUIDELINES: A REAL-WORLD PROSPECTIVE STUDY OF THE FRANCECOAG PUPS COHORT Paul Saultier
OR02 WITHIN-PATIENT COMPARISON OF TREATMENT PATTERNS BEFORE AND AFTER SWITCHING TO RFVIIIFC: A REPORT FROM THE UK NATIONAL HAEMOPHILIA DATABASE Martin Scott
OR03 INHIBITOR INCIDENCE IN PUPS WITH SEVERE HAEMOPHILIA B IS HIGHER THAN USUALLY REPORTED; DATA FROM THE PEDNET REGISTRY Marijke Van Den Berg
OR04 COMORBIDITIES EXPLAIN THE AGE-RELATED INCREASE OF VON WILLEBRAND FACTOR IN PATIENTS WITH TYPE 1 VON WILLEBRAND DISEASE Ferdow Atiq
OR05 PHASE 1/2 TRIAL OF SINGLE AND MULTIPLE DOSE SUBCUTANEOUSLY ADMINISTERED FACTOR IX VARIANT CB 2679D/ISU304: PHARMACOKINETICS, ACTIVITY AND SAFETY Howard Levy
OR06 PERIOPERATIVE MANAGEMENT FOR PATIENTS WITH CONGENITAL FACTOR XI DEFICIENCY Chatree Chai-Adisaksopha
OR07 OCCURENCE AND IMPACT OF PAIN AMONG PATIENTS LIVING WITH HEMOPHILIA: AN ANALYSIS FROM THE PATIENT REPORTED OUTCOMES, BURDENS AND EXPERIENCES (PROBE) STUDY Mark W. Skinner
OR08 PERIOPERATIVE MANAGEMENT IN PATIENTS WITH HEMOPHILIA RECEIVING FITUSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC TARGETING ANTITHROMBIN FOR THE TREATMENT OF HEMOPHILIA Claude Negrier
OR09 PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD) AND PK/PD RELATIONSHIPS OF EMICIZUMAB IN PERSONS WITH HAEMOPHILIA A (PWHA) WITH INHIBITORS FROM ADOLESCENT/ADULT (HAVEN 1) AND PAEDIATRIC (HAVEN 2) PHASE 3 STUDIES Christophe Schmitt
OR10 EMICIZUMAB PROPHYLAXIS IN PAEDIATRIC PERSONS WITH HAEMOPHILIA A (PWHA) WITH INHIBITORS: IMPACT ON HEALTH-RELATED OUTCOMES AND CAREGIVER BURDEN IN THE HAVEN 2 STUDY Maria Elisa Mancuso
10:00 – 10:30 Coffee Break/Poster Viewing  Poster & Catering Area
10:30 – 12:00 SESSION 7: Innovations in Haemophilia Treatment Chairs: Gerry Dolan and Carmen Altisent Auditorio A / Plenary Hall
Gene therapy for hemophilia: an update Frank Leebeek
Immunogenicity of new treatments: Current status of knowledge David Lillicrap
Factor assays in the era of new therapies Steve Kitchen
12:00 – 12:30 AROSENIUS LECTURE 2018 Chairs: Víctor Jiménez Yuste and Jan Astermark Auditorio A / Plenary Hall
Ageing and haemophilia Evelien Mauser-Bunschoten
12:30 – 12:45 POSTER AND RESEARCH AWARDS  Chair: Michael Makris Auditorio A / Plenary Hall
12:45 – 13:45 SESSION 8: HOT TOPICS Chairs: Michael Makris and Víctor Jiménez Yuste Auditorio A / Plenary Hall
OR11 ACHIEVEMENT OF NORMAL FACTOR VIII ACTIVITY FOLLOWING BMN 270 AAV5-FVIII GENE TRANSFER: LONG-TERM EFFICACY AND SAFETY FROM A PHASE 1/2 STUDY IN PATIENTS WITH SEVERE HEMOPHILIA A Benjamin Kim
OR12 SPK-9001: ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER FOR HEMOPHILIA B – SUSTAINED FIX ACTIVITY AND PERSISTENT PROPHYLACTIC BENEFIT AT 1 YEAR Spencer K. Sullivan
OR13 SPK-8011: PRELIMINARY RESULTS FROM A PHASE 1/2 TRIAL OF INVESTIGATIONAL GENE THERAPY FOR HEMOPHILIA A Spencer K. Sullivan
OR14 ENDOGENOUS FIX EXPRESSION AND REDUCED ANNUAL BLEED RATE FOLLOWING AMT-060 (AAVHFIX) IN ADULTS WITH SEVERE OF MODERATE-SEVERE HEMOPHILIA B: INTERIM RESULTS UP TO 1.5 YEARS FROM A PHASE I/II DOSE-ESCALATION STUDY Wolfgang Miesbach
13:45 – 14:00 CLOSING REMARKS Víctor Jiménez-Yuste Auditorio A / Plenary Hall
14:00-15:00 Lunch  Poster & Catering Area